Lacosamide accepted for use in NHS Scotland
Lacosamide (Vimpat) has been accepted for use in NHS Scotland for thetreatment of epilepsy in patients aged 16 years and over with partialonset seizures, as an add-on to existing therapy, following the latestround of assessments by the Scottish Medicines Consortium. Use oflacosamide is restricted to patients with refractory epilepsy
Lacosamide (Vimpat) has been accepted for use in NHS Scotland for the treatment of epilepsy in patients aged 16 years and over with partial onset seizures, as an add-on to existing therapy, following the latest round of assessments by the Scottish Medicines Consortium. Use of lacosamide is restricted to patients with refractory epilepsy.
Doripinem (Doribax) has been accepted for restricted use as a second- or third-line treatment for adults with complicated intra-abdominal infection that is resistant to current conventional treatments.
Fentanyl buccal tablets (Effentora) and sublingual tablets (Abstral) have been accepted for the treatment of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Use of these drugs should be restricted to patients who are unsuitable for other short-acting opioids.
Also accepted for use are sugammadex (Bridion) and adalimumab (Humira). Sugammadex is accepted for restricted use for the immediate reversal of rocuronium-induced neuromuscular blockade, in adults only.
Adalimumab is accepted for use in combination with methotrexate (or as a monotherapy when methotrexate is inappropriate or not tolerated) for the treatment of active polyarticular juvenile idiopathic arthritis in adolescents aged 13–17 years who have an inadequate response to one or more disease-modifying antirheumatic drugs restricted to use within specialist rheumatology services.
Lapatinib (Tyverb), etravirine (Intelence), extended release epidural morphine (Depodur), etonogestrel 11.7mg/ethinylestradiol 2.7mg contraceptive vaginal ring (NuvaRing) and Pemetrexed (Alimta), in combination with cisplatin for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, were not recommended.
Citation: The Pharmaceutical Journal URI: 10049454
Recommended from Pharmaceutical Press